Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3772460 | 0.85 | RAB9A (0.41) | TP53ALDH1A1GAATDP1L3MBTL1 | |
| SCHEMBL3782593 | 0.85 | ALDH1A1 (0.42) | HSD17B10USP2TP53ALDH1A1ATM | |
| SCHEMBL3771889 | 0.79 | BRD4 (0.35) | ALDH1A1TSHRGAAKMT2ALMNA | |
| SCHEMBL3781282 | 0.77 | POLA1 (0.32) | HTT | |
| SCHEMBL3770319 | 0.77 | KDM4E (0.33) | KDM4ELMNA | |
| SCHEMBL3772372 | 0.77 | HSD17B10 (0.44) | HSD17B10ALDH1A1KMT2ATDP1KDM4E | |
| SCHEMBL3772575 | 0.75 | TNF (0.35) | HSD17B10ALDH1A1KMT2AL3MBTL1KDM4E | |
| SCHEMBL3772462 | 0.73 | — | — | |
| SCHEMBL3781323 | 0.72 | BRD4 (0.31) | — | |
| SCHEMBL3780803 | 0.69 | ALDH1A1 (0.40) | TP53ALDH1A1GAAKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324305-A1 | PRODUCTION METHOD OF POLYCYCLIC LACTAMS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20090118519-A1 | Production Method of Polycyclic Lactams | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-2014647-A1 | PROCESS FOR PRODUCING POLYCYCLIC LACTAM | Sumitomo Chemical Company, Limited (JP) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118519-A1 | Production Method of Polycyclic Lactams | MRPL21, COASY, ASNS | HSD17B10 256/4885USP2 1920/4885TP53 4211/4885 |
| US-20100324305-A1 | PRODUCTION METHOD OF POLYCYCLIC LACTAMS | COASY, MRPL21, ASNS | HSD17B10 234/4885USP2 1726/4885TP53 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.